Summary
10.66 0.18(1.72%)07/05/2024
Roivant Sciences Ltd. Common Shares (ROIV)
Roivant Sciences Ltd. Common Shares (ROIV)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.72 | 5.27 | 8.53 | -19.44 | 0.28 | 80.46 | 0.00 | -51.90 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 10.66 | |
| Open | 10.48 | |
| High | 10.67 | |
| Low | 10.34 | |
| Volume | 2,957,867 | |
| Change | 0.18 | |
| Change % | 1.72 | |
| Avg Volume (20 Days) | 3,735,914 | |
| Volume/Avg Volume (20 Days) Ratio | 0.79 | |
| 52 Week Range | 5.02 - 13.24 | |
| Price vs 52 Week High | -19.49% | |
| Price vs 52 Week Low | 112.35% | |
| Range | 0.00 | |
| Gap Up/Down | -0.45 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,867 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 12.20 | |
| Book Value | 2.9760 | |
| Earnings Per Share | -4.6990 | |
| EPS Estimate Current Quarter | -0.1500 | |
| EPS Estimate Next Quarter | -0.2300 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | -0.6100 | |
| Diluted EPS (TTM) | -4.6990 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -38.4514 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 42,618,000 | |
| Revenue per share TTM | 0.1890 | |
| Quarterly Revenue Growth (YOY) | 9.5720 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 21,738,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 684,788,992 | |
| Shares Float | 166,766,706 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 53.43 | |
| Institutions (%) | 36.03 | |
06/07 18:26 EST - seekingalpha.com
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, and Haliburton. Many of the ideas included have not been discussed in months on the site. One of the ideas is actually first-ever coverage for this ticker.
06/02 07:27 EST - seekingalpha.com
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Genevant and Arbutus offer potential litigation value of $5-10 billion against Moderna and Pfizer.
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Roivant Sciences' stock is undervalued with a market cap of $8.37 billion and $6 billion in cash. The company holds stakes in biotech companies worth billions, including Immunovant and Arbutus. Genevant and Arbutus offer potential litigation value of $5-10 billion against Moderna and Pfizer.
05/30 09:21 EST - zacks.com
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25.
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25.
05/30 07:00 EST - globenewswire.com
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update.
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update.
05/16 16:05 EST - globenewswire.com
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update.
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update.
05/07 14:04 EST - investorplace.com
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.
05/01 10:47 EST - investorplace.com
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Finding firms with strong growth potential is essential for healthcare investors looking for large profits. Three exceptional firms have surfaced as strong healthcare stocks.
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
Finding firms with strong growth potential is essential for healthcare investors looking for large profits. Three exceptional firms have surfaced as strong healthcare stocks.
04/25 08:00 EST - businesswire.com
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung). Approximately 200,000 people in the U.S. (and more than 1 million worldwide) are estimated to have sarcoidosis, an i.
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
BASEL, Switzerland & LONDON & NEW YORK--(BUSINESS WIRE)--Roivant (Nasdaq: ROIV) and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung). Approximately 200,000 people in the U.S. (and more than 1 million worldwide) are estimated to have sarcoidosis, an i.
04/02 09:38 EST - investors.com
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
Roivant stock is nearing a breakout Tuesday after the company announced positive results in an eye-disease study and a $1.5 billion buyback.
Roivant Sciences Stock Flirts With Breakout On 'Extremely Positive' Eye-Disease Study
Roivant stock is nearing a breakout Tuesday after the company announced positive results in an eye-disease study and a $1.5 billion buyback.
04/02 07:28 EST - reuters.com
Roivant's anti-inflammatory drug succeeds in mid-stage study
Roivant Sciences said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's shares up 8% in premarket trading.
Roivant's anti-inflammatory drug succeeds in mid-stage study
Roivant Sciences said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's shares up 8% in premarket trading.
04/02 07:00 EST - globenewswire.com
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
BASEL, Switzerland and LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. Roivant also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the company's common shares, including the repurchase of all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share. The aggregate purchase price for the Sumitomo Pharma transaction is approximately $648.4 million and will reduce Roivant's shares outstanding as of February 9, 2024 by approximately 9%.
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
BASEL, Switzerland and LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Priovant Therapeutics today announced positive results from the Phase 2 study (NEPTUNE) evaluating brepocitinib in non-anterior non-infectious uveitis (NIU), showing the strongest efficacy data in NIU observed to date. Roivant also announced that its board of directors has authorized a share repurchase program for up to $1.5 billion of the company's common shares, including the repurchase of all 71.3 million shares held by Sumitomo Pharma at a purchase price of $9.10 per share. The aggregate purchase price for the Sumitomo Pharma transaction is approximately $648.4 million and will reduce Roivant's shares outstanding as of February 9, 2024 by approximately 9%.
02/13 12:02 EST - seekingalpha.com
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
Roivant Sciences Ltd. (ROIV) Q3 2023 Earnings Call Transcript
02/13 07:00 EST - globenewswire.com
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update.
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2023, and provided a business update.
01/07 13:15 EST - seekingalpha.com
Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy
Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievements include the sale of Telavant to Roche, the successful performance of Vtama cream for psoriasis, and advancements in clinical trials for atopic dermatitis and IMVT-1402 antibody development. Despite the lack of immediate catalysts and ongoing cash burn, the stock trades at a substantial discount relative to its sector, making it a "buy" at current levels.
Roivant Sciences: Why Its 'Vant' Biotech Model Is A Buy
Roivant Sciences operates with an innovative business model through its subsidiaries, specializing in specific therapeutic areas such as immuno-dermatology and autoimmune disorders. Notable achievements include the sale of Telavant to Roche, the successful performance of Vtama cream for psoriasis, and advancements in clinical trials for atopic dermatitis and IMVT-1402 antibody development. Despite the lack of immediate catalysts and ongoing cash burn, the stock trades at a substantial discount relative to its sector, making it a "buy" at current levels.
12/20 16:30 EST - globenewswire.com
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves' disease meaningfully exceeded 50% response rates.
12/14 09:00 EST - globenewswire.com
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the rights in the US and Japan to RVT-3101, a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Prior to the closing of the transaction, Roivant owned 75% of the issued and outstanding shares of common stock and preferred stock of Telavant, on an as-converted basis. An additional payment of $150 million in cash is payable upon the completion of a near-term milestone.
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
BASEL, Switzerland and LONDON and NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the rights in the US and Japan to RVT-3101, a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Prior to the closing of the transaction, Roivant owned 75% of the issued and outstanding shares of common stock and preferred stock of Telavant, on an as-converted basis. An additional payment of $150 million in cash is payable upon the completion of a near-term milestone.
11/27 12:51 EST - proactiveinvestors.com
Roivant Sciences unable to determine effectiveness of lupus drug in Phase 2 study
Roivant Sciences stock moved lower on Monday after the biopharmaceutical company announced that its lupus therapeutic oral brepocitinib failed to meet the primary endpoint in a Phase 2 study. The company said it plans to continue progressing the drug in other indications outside of Systemic Lupus Erythematosus (SLE) given its favorable safety and tolerability profile, six other positive Phase 2 studies, and the active arm performance of this study.
Roivant Sciences unable to determine effectiveness of lupus drug in Phase 2 study
Roivant Sciences stock moved lower on Monday after the biopharmaceutical company announced that its lupus therapeutic oral brepocitinib failed to meet the primary endpoint in a Phase 2 study. The company said it plans to continue progressing the drug in other indications outside of Systemic Lupus Erythematosus (SLE) given its favorable safety and tolerability profile, six other positive Phase 2 studies, and the active arm performance of this study.
11/27 08:52 EST - marketwatch.com
Roivant Sciences shares drop as lupus treatment misses trial goal
Roivant Sciences Ltd. shares ROIV fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to severe lupus.
Roivant Sciences shares drop as lupus treatment misses trial goal
Roivant Sciences Ltd. shares ROIV fell 3% premarket on Monday after the company said the experimental treatment brepocitinib failed to meet its main goal in a trial involving patients with moderate to severe lupus.
11/27 08:49 EST - reuters.com
Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study
Roivant Sciences said on Monday its experimental drug to treat autoimmune disease systemic lupus erythematosus (SLE) failed to meet the main goal of reducing symptoms in a mid-stage study.
Roivant Sciences' lupus drug fails to reduce symptoms in mid-stage study
Roivant Sciences said on Monday its experimental drug to treat autoimmune disease systemic lupus erythematosus (SLE) failed to meet the main goal of reducing symptoms in a mid-stage study.
11/13 19:19 EST - seekingalpha.com
Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matt Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief Investment Officer Frank Torti - Managing Director, Vant Chair Conference Call Participants David Risinger - Leerink Partners Brian Cheng - JPMorgan Yaron Werber - TD Cowen Corinne Jenkins - Goldman Sachs Robyn Karnauskas - Truist Securities Louise Chen - Cantor Fitzgerald Douglas Tsao - H.C.
Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Company Participants Stephanie Lee - Vice President, Special Projects Matt Gline - Chief Executive Officer Mayukh Sukhatme - President and Chief Investment Officer Frank Torti - Managing Director, Vant Chair Conference Call Participants David Risinger - Leerink Partners Brian Cheng - JPMorgan Yaron Werber - TD Cowen Corinne Jenkins - Goldman Sachs Robyn Karnauskas - Truist Securities Louise Chen - Cantor Fitzgerald Douglas Tsao - H.C.